Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI

Profusa, Inc.

Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).
Collaboration to support U.S. commercialization of Lumee wearable continuous tissue oxygen monitoring for critical limb ischemia.
Potential new indications include cardiovascular, renal, multi-organ, and orthopedic postoperative perfusion monitoring.
Profusa CEO notes over $100M invested in Lumee; Mayo retains financial interest for not-for-profit mission.
Financial terms include royalties on net sales, milestone payments, and share of sublicense income.

item 1.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-016496
form_type: 8-K
ticker: PFSA
cik: 0001859807
company_name: Profusa, Inc.
filed_at: 2026-02-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.585084+00:00
generated_at: 2026-05-16T02:49:51.790404+00:00
sec_items: ["1.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-016496
json_url: https://secwatch.observer/filing/0001213900-26-016496.json
markdown_url: https://secwatch.observer/filing/0001213900-26-016496.md
text_url: https://secwatch.observer/filing/0001213900-26-016496.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1859807/000121390026016496/0001213900-26-016496-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1859807/000121390026016496/ea0277026-8k_profusa.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-26-016496

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.